logo

For the Inventor, By the Inventor

Stamford, CT, United States of America

Loxo Oncology, Inc.


USPTO Granted Patents = 35

% Expired Patents = 17.1



Forward Citations = 72

Loading Chart...
Loading Chart...

34 inventors (with patents filed for the assignee):

goldMedal Charles Todd Eary (11 out of 17 patents)

silverMedal Nicolas Guisot (11 out of 11 patents)

bronzeMedal Nisha Nanda (9 out of 9 patents)

4.  Gabrielle R Kolakowski (8 out of 58 patents)

5.  Barbara J Brandhuber (8 out of 32 patents)

6.  Mark A Reynolds (8 out of 29 patents)

7.  Stacey Spencer (7 out of 10 patents)

8.  Steven Wade Andrews (6 out of 98 patents)

9.  James F Blake (5 out of 113 patents)

10.  Joshua H Bilenker (5 out of 5 patents)

11.  Steven A Smith (4 out of 7 patents)

12.  Adam Wade Cook (3 out of 41 patents)

13.  Tony P Tang (3 out of 44 patents)

14.  Andrew T Metcalf (3 out of 29 patents)

15.  Michael Cox (3 out of 3 patents)


Core Competencies:
Bruton's Tyrosine Kinase
Pyrazolopyrimidine Derivatives
Kinase Inhibitors
Pediatric Cancers
Liquid Formulations
Spray-Dried Dispersions
Point Mutations
Cancer Treatment
Formulations
Compounds
TRK Inhibitors

35 patents:

1. 12551463 - Dosing of a Bruton's tyrosine kinase inhibitor (2026-02-17),
2. 12268666 - Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide (2025-04-08),
3. 12220401 - Compounds useful as kinase inhibitors (2025-02-11),
4. 12138250 - Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2024-11-12),
5. 12109193 - Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide (2024-10-08),
6. 12102621 - Formulations of 6-(2-hydroxy-methylpropoxy-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2024-10-01),
7. 11963950 - Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2024-04-23),
8. 11826351 - Compounds useful as kinase inhibitors (2023-11-28),
9. 11807651 - Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2023-11-07),
10. 11484535 - Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide (2022-11-01),
11. 11471441 - Compounds useful as kinase inhibitors (2022-10-18),
12. 11214571 - Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof (2022-01-04),
13. 11191766 - Methods of treating pediatric cancers (2021-12-07),
14. 11098064 - Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbontrile (2021-08-24),
15. 11091486 - Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof (2021-08-17),
Company Overview
Loxo Oncology, Inc. is a biopharmaceutical company based in Stamford, Connecticut, focused on developing targeted therapies for patients with genetically defined cancers. The company specializes in precision medicine, leveraging its expertise in molecular biology and genomics to create innovative treatments that address specific genetic mutations. Loxo's research efforts are aimed at advancing the understanding of cancer biology and improving patient outcomes through tailored therapeutic approaches.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Loxo Oncology, Inc. USPTO Patent Assignee Logo
35 Patents

#30 in Stamford, CT

#249 in Connecticut

#9,756 in US

#19,181 in the World

Stamford, CT (US)
Stamford, CT, United States of America

Loxo Oncology, Inc.

Forward Citations = 72

34 inventors:

goldMedal Charles Todd Eary (11 out of 17 patents)

silverMedal Nicolas Guisot (11 out of 11 patents)

bronzeMedal Nisha Nanda (9 out of 9 patents)

4.  Gabrielle R Kolakowski (8 out of 58 patents)

5.  Barbara J Brandhuber (8 out of 32 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Loxo Oncology, Inc.. Retrieved from https://idiyas.com/company/loxo-oncology

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…